218 related articles for article (PubMed ID: 25644037)
1. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.
Michaelis M; Agha B; Rothweiler F; Löschmann N; Voges Y; Mittelbronn M; Starzetz T; Harter PN; Abhari BA; Fulda S; Westermann F; Riecken K; Spek S; Langer K; Wiese M; Dirks WG; Zehner R; Cinatl J; Wass MN; Cinatl J
Sci Rep; 2015 Feb; 5():8202. PubMed ID: 25644037
[TBL] [Abstract][Full Text] [Related]
2. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
4. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
5. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
6. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
8. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
[TBL] [Abstract][Full Text] [Related]
9. Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
Yang B; Reynolds CP
Clin Cancer Res; 2005 Apr; 11(7):2774-80. PubMed ID: 15814660
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
11. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
12. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Voges Y; Michaelis M; Rothweiler F; Schaller T; Schneider C; Politt K; Mernberger M; Nist A; Stiewe T; Wass MN; Rödel F; Cinatl J
Cell Death Dis; 2016 Oct; 7(10):e2410. PubMed ID: 27735941
[TBL] [Abstract][Full Text] [Related]
13. Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells.
Zhuang ZG; Fei F; Chen Y; Jin W
Acta Pharmacol Sin; 2008 Dec; 29(12):1459-66. PubMed ID: 19026165
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
15. A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53.
Bechill J; Zhong R; Zhang C; Solomaha E; Spiotto MT
PLoS One; 2016; 11(4):e0154125. PubMed ID: 27124407
[TBL] [Abstract][Full Text] [Related]
16. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
18. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
Ribas J; Boix J; Meijer L
Exp Cell Res; 2006 Jul; 312(12):2394-400. PubMed ID: 16765943
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
Giono LE; Manfredi JJ
Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]